PCM
JBIO

Prelude Capital Management’s Jade Biosciences JBIO Stock Holding History

Prelude Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,127
Closed -$290K – 1195
2024
Q4 		$290K Buy
+3,127
New +$269K 0.02% 813
2024
Q2 		– Sell
-591
Closed -$612K – 1219
2024
Q1 		$612K Buy
+591
New +$451K 0.03% 547

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prelude Capital Management's JBIO Position: Q1 2025 in Review

Prelude Capital Management sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 3,127 shares — an estimated $290K sold.

Prelude Capital Management first reported a position in JBIO in Q1 2024 and held it in 2 quarters. The position peaked at $612K in Q1 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

  • Prelude Capital Management reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 3,127 Jade Biosciences shares in Q1 2025, an estimated $290K.
  • Prelude Capital Management first reported a position in Jade Biosciences in Q1 2024 and held it in 2 quarters.
  • Prelude Capital Management's Jade Biosciences position peaked at $612K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.